BPCL partners with GPS Renewables to set up compressed biogas plants across India
By Aditya Bhagchandani Published on April 23, 2025, 17:06 IST
Bharat Petroleum Corporation has officially entered into a joint venture with Bengaluru-based GPS Renewables to establish Compressed Biogas (CBG) plants across India. The agreement was signed on April 23, 2025, as part of BPCL's broader strategy to support India's clean energy goals and meet upcoming CBG blending obligations. 50:50 joint venture for clean energy expansion
As per the agreement, BPCL and GPS Renewables will each hold a 50% stake in the newly formed private joint venture company. The initial paid-up capital of the JV stands at Rs 8 crore, equally subscribed by both entities. The authorised share capital is set at Rs 200 crore, indicating significant scale and expansion potential.
The scope of this JV includes the construction, operation, and maintenance of CBG plants, as well as the sale of biogas and its derivatives across India. Governance and structure
The JV will operate as a private limited company, with equal rights granted to both partners in terms of director appointments. BPCL will nominate the first chairman, while the CEO and CFO positions will rotate every three years, starting with the CEO from GPS and CFO from BPCL.
This move aligns with BPCL's energy transition and net-zero initiatives, reinforcing its position in the renewable energy space. FAQs
What is the purpose of BPCL's joint venture with GPS Renewables?
To construct and operate Compressed Biogas plants across India and support BPCL's green energy and net-zero goals.
What is the shareholding ratio in the joint venture?
BPCL and GPS Renewables each hold a 50% stake.
How much capital is being infused initially?
Rs 8 crore as paid-up capital, with an authorised capital of Rs 200 crore.
Will this joint venture impact BPCL's CBG blending targets?
Yes, it is intended to help BPCL meet mandated CBG blending obligations in the coming years.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Hologic Climbs 13% in a Month: How Should You Play the Stock?
After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively. The current price is now 23.9% above the 52-week low of $51.90, boosted in part by reports that Hologic declined a private takeover bid from TPG and Blackstone. HOLX has also managed to outperform two of its key competitors — Exact Sciences EXAS and Becton, Dickinson and Company BDX, or BD, in the same time frame. Image Source: Zacks Investment Research Investor sentiment was already subdued after the release of the company's fiscal 2025 second-quarter earnings in early May. Hologic met adjusted EPS expectations with a modest revenue beat but revised its annual outlook due to the growing tariff impact from China and Costa Rica, funding cuts affecting the Africa business, and a soft capital equipment market. In contrast, Exact Sciences anticipates 'little to no tariff impact' due to all domestic operations, while BD expects $90 million in tariff expenses for fiscal 2025, mostly from China imports. That said, let's explore what might be driving Hologic's recent rally. On May 27, HOLX shares rose nearly 15% following a report from the Financial Times that the company turned down a non-binding offer from private equity (PE) firms TPG and Blackstone. The deal was valued at up to $16.7 billion, including debt. These firms, known for their solid history of healthcare investments, teamed up last year to explore a potential acquisition of Bausch + Lomb, which eventually did not happen. The proposed takeover bid of Hologic would have been one of the largest leveraged buyouts of the year, valuing the company's shares between $70 and $72 — roughly a 30% premium to the May 23 closing price of $54.28. The report also stated that there is a possibility the deal discussions might resume, according to people with knowledge of the matter. Hologic has attracted buyers' attention for a while now. Of late, the take-private activities by PE firms have seen a sharp increase, such as Sycamore Partners' $24 billion deal for Walgreens Boots Alliance, Thoma Bravo's $10.6 billion acquisition of Boeing's software unit, and 3G Capital's $10.5 billion deal for Skechers. Nonetheless, the high premium in the offer signals strong confidence in Hologic's growth potential. The company presented new data showing the significant clinical impact of the Breast Cancer Index ('BCI') test at the 2025 American Society of Clinical Oncology Annual Meeting held on June 2. The molecular, gene expression-based test from Hologic's subsidiary, Biotheranostics, has been a key growth driver in the molecular diagnostics business over the past few quarters. The latest data from the prospective, multi-center BCI Registry Study highlights how this genomic test plays a critical role in guiding extended endocrine therapy decisions for women with early-stage, hormone receptor-positive (HR+) breast cancer. With more than 2,800 patients involved, the study found that BCI testing led to a change in treatment recommendations for about four in 10 cases. Additionally, physicians' confidence in their treatment recommendations got a boost, while patients felt comfortable in their decisions, citing fewer concerns about cost, drug safety and preference related to extended endocrine therapy benefits. Hologic looks attractive from a valuation standpoint. The stock has been trading at a price-to-sales (P/S) of 3.40X over the past five years compared to its median of 4.33X and the industry average of 4.16X. It has a Value Score of B at present. Image Source: Zacks Investment Research Meanwhile, both Exact Sciences and BD are trading at a premium to their industry average, with P/S of 3.16X and 2.20X respectively. Molecular Diagnostics assays are likely to continue to be the principal revenue-generating component in the Diagnostics division. As Hologic drives awareness and reimbursement in the highly unpenetrated U.S. vaginitis market, the BV CV/TV assay is poised to see a strong uptake. Aligning with its long-term revenue diversification strategy, the company's Breast Health service revenues are now larger and growing more steadily than the gantry business. The 2024 acquisition of Endomagnetics boosted the Interventional Breast portfolio with market-leading product lines and strong R&D capabilities for further portfolio expansion. The upcoming launch of innovations like the Envision Mammography Platform is likely to gain a favorable reception. In Surgical, Myosure's strong international growth points to the high demand for minimally invasive options for treating uterine polyps and fibroids. Hologic continues to expand this division both organically and through acquisitions such as Gynsesonics, leveraging its established sales channel. Further, the company is building capabilities to grow internationally on a consistent basis by going directly into more geographies and businesses. A consistently strong profitability has contributed to a fortress balance sheet over time, allowing Hologic to execute on both tuck-in M&A and share repurchases. Based on short-term price targets offered by 15 analysts, the Zacks average price target is $68.13 per share. The average suggests a potential 8.02% upside from last Friday's closing price. Image Source: Zacks Investment Research Hologic has some promising catalysts for long-term expansion, supported by an attractive valuation relative to its industry. However, despite outperforming peers over the past month, the Zacks Rank #3 (Hold) stock is navigating a turbulent macroeconomic landscape, which is expected to weigh on its financial performance in the near term. Hence, those eyeing HOLX may find it wise to wait for a better entry point, while current shareholders should retain their position. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Ecksand Awarded the Canadian National Mark, a Rare Honour in Fine Jewellery
Toronto, Ontario--(Newsfile Corp. - June 9, 2025) - Ecksand, the Montreal-based fine jewellery maison known for its ethical Canadian-made craftsmanship, has officially been awarded the Canadian National Mark, a prestigious designation granted by the Commissioner of Competition. Under the Precious Metals Marking Act, this government-regulated hallmark confirms that each Ecksand piece is made in Canada, from gemstone sourcing to final polish, under strict standards of quality and traceability. With only 108 National Mark certificates issued to date, and estimates showing that even fewer brands have been able to maintain this standard in recent years, this award is a rare distinction in the jewellery world, placing Ecksand among an elite group of brands recognized for genuine Canadian production. Unlike typical "Made in Canada" labels, the National Mark demands verified local manufacturing, traceable materials and compliance with stringent purity and quality standards, making it one of the highest acknowledgements of authenticity and trust in a brand. For Ecksand, this recognition is more than a stamp. It is a powerful affirmation of the maison's commitment to transparency, ethical sourcing and artisanal integrity. In an industry where vague origin claims are common, the Canadian National Mark sets Ecksand apart with certified accountability. "At Ecksand, sustainability isn't just a responsibility, it's part of our design and craftsmanship philosophy. Every detail, from our ethical noble materials to the thoughtful sculpting of each piece, is guided by the belief that beauty should last," says Erica Bianchini, Ecksand's Creative Director. "The Canadian National Mark affirms what we've always stood for: transparency, artistry and craftsmanship rooted here at home." Founded in 2009, Ecksand has built a reputation for creating fine jewellery with purpose. With a fully vertical, green atelier in Montreal, the maison oversees every step of its jewellery-making process in-house, producing heirloom-quality engagement rings and handcrafted bracelets, necklaces and earrings. Each piece is a reflection of Ecksand's artisanal skill and environmental care. Not only does this ensure full creative control, it also guarantees a transparent supply chain and sustainable practices that align with the values of today's discerning buyer. The Canadian National Mark now serves as formal recognition of these long-standing commitments and reinforces the maison's mission to deliver responsible luxury that lasts for generations. Explore Ecksand's certified collections and learn more about the Canadian National Mark at About: Founded in 2009, Ecksand is a French-Canadian fine jewellery Maison renowned for its iconic collections and sustainable practices. Headquartered in Montreal, the brand is led by Creative Director Erica Bianchini, whose creative vision guides a passionate team dedicated to crafting high-end jewellery that combines responsibly sourced materials with artisanal manufacturing. This year, Ecksand was officially awarded the Canadian National Mark—a rare hallmark granted by the Commissioner of Competition under the Precious Metals Marking Act. With only a handful of National Mark certificates issued to date, this prestigious designation confirms that every Ecksand piece is a Product of Canada, made under strict standards of traceability and quality. The award affirms the Maison's long-standing commitment to transparency, ethical sourcing, and exceptional Canadian craftsmanship. As one of the leading Canadian jewelers in sustainable luxury, Ecksand prides itself on its eco-conscious ethos. Every creation begins with Erica Bianchini's thoughtful design vision, paired with precise engineering to ensure exceptional quality. From there, noble materials—such as recycled gold and traceable natural gemstones—are brought to life through meticulous craftsmanship. Each ring spends at least six hours in the hands of Ecksand's skilled artisans, undergoing a multi-step process rooted in time-honoured techniques. Ecksand doesn't count the hours it takes to perfect a piece—it trusts the expert workmanship established in its state-of-the-art workshop. Every jewel is handcrafted in Ecksand's fully green, vertically integrated Montreal atelier—an environment optimized for minimal environmental impact. There, each piece undergoes final polishing, inspection, and refinement to meet the Maison's highest standards. With a focus on iconic design, Ecksand offers a curated selection of bridal and fine jewelry, including signature collections such as The Mark, Duel, Arctic Dragon, and Starlight. Featuring handcrafted engagement rings, diamond earrings, and one-of-a-kind gemstone pieces that honour the Maison's French-Canadian artisanal heritage, Ecksand continues to champion its mission of responsible luxury made to last for generations. This commitment has brought Ecksand to red carpets from the Oscars to New York Fashion Week, as the Maison's timeless artistry becomes a staple among international celebrities. Ecksand is available online and ships internationally. The brand also welcomes clients at its Montreal and Toronto boutiques, where personalized consultations can be booked for a tailored shopping experience. Alanna Arsenault alanna@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Axios
38 minutes ago
- Axios
Amid backlash, Tesla remained resilient in Texas
Even as Tesla deliveries plunged nationally this year amid Elon Musk's very visible (if short-lived) alliance with President Trump, there was at least one state where Tesla registrations were up: Texas. Why it matters: The registration data, obtained by Axios through public information requests, indicates loyalty to the brand in its home base, including Texas' large urban and suburban counties. The depth of conservatives' enthusiasm for Musk's automobiles now faces a major test amid the absolute meltdown last week between the Tesla CEO and the president. By the numbers: Texans registered 12,918 new Teslas in the first three months of 2025, a period when Musk, who contributed more than $250 million to a pro-Trump super PAC during the 2024 election campaign, was enmeshed in the Trump administration as the overseer of DOGE, the president's cost-cutting initiative. Over the same period in 2024, Texans registered 10,679 Teslas. That's a 21% increase year over year. The intrigue: The spike in Texas registrations came as Tesla was flailing elsewhere. Tesla's vehicle deliveries plunged 13% globally in the first quarter of 2025 (336,681 electric vehicles) compared with Q1 2024 (386,810). Tesla vehicles were torched at showrooms and the brand's reputation cratered. Zoom in: Tesla saw year-over-year improvements in its sales in some of the most populous Texas counties. In Travis County, new Tesla registrations grew from 1,369 in the first quarter of 2024 to 1,424 during the first quarter of 2025. In Harris County, they grew from 1,526 to 1,837 during the same period. Tesla registration grew from 1,316 to 1,546 in Collin County and from 990 to 1,146 in Dallas County. In Bexar County, registrations grew from 631 to 664. What they're saying:"It's homegrown pride," is how Matt Holm, president and founder of the Tesla Owners Club of Austin, explains the car company's resilience to Axios. "And regardless of all the drama going on these days, people can differentiate between the product and everything else going on, and it's just a great product." "Elon has absolutely and irreversibly blown up bridges to some potential customers," says Alexander Edwards, president of California-based research firm Strategic Vision, which has long surveyed the motivations of car buyers. "People who bought Teslas for environmental friendliness, that's pretty much gone," Edwards tells Axios. Yes, but: The company had been enjoying an increasingly positive reputation among more conservative consumers. Musk was viewed favorably by 80% of Texas Republicans polled by the Texas Politics Project in April — and unfavorably by 83% of Democrats. In what now feels like a political lifetime ago, Trump himself even promoted Teslas by promising to buy one in support of Musk earlier this year. "In some pockets, like Austin, you have that tech group that loves what Tesla has to offer, can do some mental gymnastics about Musk, and looks at Rivian and says that's not what I want or might be priced out," Edwards says. Between the lines:"Being in the state of Texas, you're naturally conditioned to think you're better than everyone else in the U.S. And when you buy a Tesla" — a status symbol — "that's what you're saying. It doesn't surprise me that there's an increase in sales" in Texas, Edwards says. Plus: Tesla's resilience in Texas could have practical reasons as well, Edwards says. Texas homes — as opposed to, say, apartments in cities on the East Coast — are more likely to have a garage to charge a car in, he adds. What's next: Musk said late last month that Tesla was experiencing a "major rebound in demand" — without providing specifics. But that was before things went absolutely haywire with Trump and Tesla stock took a bath last week.
